(Total Views: 640)
Posted On: 08/25/2023 4:22:13 AM
Post# of 155364
But isn't this a problem for Merck?
They need to extend patent protection for Keytruda to keep the cheap generic drug producers out of the market. If they fail to do so (by switching to Leronlimab and losing Keytruda patent protection) the generic drug producers will take over market shares. So I guess they somehow have to keep Keytruda alive and maybe will gobble up Leronlimab on the way?
They need to extend patent protection for Keytruda to keep the cheap generic drug producers out of the market. If they fail to do so (by switching to Leronlimab and losing Keytruda patent protection) the generic drug producers will take over market shares. So I guess they somehow have to keep Keytruda alive and maybe will gobble up Leronlimab on the way?
(4)
(0)
